| Shared Labs Grant – Enhancing/Expanding SRLs | Arun Sharma | Shared Resource Laboratory for Advanced Stem Cell-Based Modeling |
$3,999,995 |
| Manufacturing Network Grant | Dr. Dhruv Sareen | A comprehensive biomanufacturing center solving bottlenecks in cell and gene therapy manufacturing to accelerate new therapies for California patients |
$2,000,000 |
| Foundation – Discovery Stage Research Projects | Tyler Mark Pierson | Modeling of GATAD2B-associated neurodevelopmental disorder and NuRDopathies: Investigation of cellular & molecular anomalies altering neurodevelopment |
$1,318,441 |
| Foundation – Discovery Stage Research Projects | Dmitriy Sheyn | The role of WNT and BMP signaling pathways in iPSC to iTenocyte step-wise differentiation for tendon repair |
$1,516,563 |
| Research Training Grant | Cedars-Sinai Medical Center Wafa Tawackoli | CIRM Training Program in Translational Regenerative Medicine |
$5,373,075 |
| Alpha Stem Cell Clinics Network Expansion | Dr. Michael I Lewis | A comprehensive stem cell and gene therapy clinic to advance new therapies for a diverse patient population in California |
$7,957,966 |
| Conference – Manage The SPARK Annual Meeting | Wafa Tawackoli | 2023 CIRM SPARK Research Conference |
$100,000 |
| Quest – Discovery Stage Research Projects | Dr. Ritchie Ho | C9orf72 repeat expansion-tuned allelic suppression by CRISPRi as an ALS therapy |
$2,274,768 |
| Quest – Discovery Stage Research Projects | Dr. Ke Liao | RNA-based therapeutics to augment regulatory T cells: a novel approach to treat myocarditis |
$2,264,509 |
| Quest – Discovery Stage Research Projects | Dmitriy Sheyn | Microgel encapsulated iPSC-derived notochordal cells to treat intervertebral disc degeneration and low back pain |
$2,020,166 |
| Quest – Discovery Stage Research Projects | Dr. Robert Barrett | A new precision medicine based iPSC-derived model to study personalized intestinal fibrosis treatments in pediatric patients with Crohn’s disease |
$776,340 |
| Quest – Discovery Stage Research Projects | Dr Eduardo Marban | New noncoding RNA chemical entity for heart failure with preserved ejection fraction. |
$1,397,412 |
| Inception – Discovery Stage Research Projects | Dmitriy Sheyn | IVD rejuvenation using iPSC-derived notochordal cells |
$241,992 |
| Inception – Discovery Stage Research Projects | Professor Clive Niels Svendsen | Blood Brain Barrier (BBB)-on-Chip: Development and validation of a novel iPS-based microfluidic model of the human BBB |
$241,992 |
| Inception – Discovery Stage Research Projects | Linda Cambier | Exosomal Y-RNAs as mediators of bioactivity of cardiac-derived cell therapy |
$181,063 |
| Diagnostic Translational Research Projects | Yuan Yuan | A Rapid Clinical Digital Patient-derived Organoid to Guide Breast Cancer Treatment Decision |
$1,535,375 |
| Therapeutic Translational Research Projects | Dr. Ahmed Gamal Ibrahim | Noncoding RNA drug TY1 as a therapeutic candidate for scleroderma and systemic sclerosis |
$2,590,224 |
| SPARK | Wafa Tawackoli | Mentored High School Summer Research Program |
$508,750 |
| SPARK | Wafa Tawackoli | Mentored High School Summer Research Program |
$296,628 |
| Conference II | Cedars-Sinai Medical Center Wafa Tawackoli | 14th Annual California ALS Research Summit |
$50,000 |
| Conference II | Wafa Tawackoli | 1st Annual Greater Los Angeles Regenerative Medicine Summit |
$30,949 |
| Conference II | Wafa Tawackoli | 13th Annual California ALS Research Summit |
$50,000 |
| Conference II | Wafa Tawackoli | Advances in Therapeutic Applications of Stem Cells |
$50,000 |
| Clinical Trial Stage Projects | Clive Svendsen | CNS10-NPC-GDNF delivered into the motor cortex for the treatment of ALS |
$11,990,372 |
| Clinical Trial Stage Projects | Clive Svendsen | Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa |
$10,444,063 |
| Clinical Trial Stage Projects | Dr. Michael I Lewis | Pulmonary Arterial Hypertension Treated with Cardiosphere-Derived Allogeneic Stem Cells |
$7,354,772 |
| Clinical Trial Stage Projects | Professor Clive Niels Svendsen | Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis |
$6,154,067 |
| Late Stage Preclinical Projects | Dr. Eugenio Cingolani | Extracellular Vesicles for Ventricular Tachycardia |
$5,999,441 |
| Late Stage Preclinical Projects | Shaomei Wang | IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa |
$4,954,514 |
| Conference | Professor Clive Niels Svendsen | California ALS Summit 2012 |
$6,825 |
| Conference | Dr. John Yu | First Annual Stem Cell Therapies for Neurological Disorders: Overcoming the Current Barriers to Clinical Translation, April 30 (special stem cell program for high school students on April 28) |
$18,500 |
| Disease Team Planning | Dr. Eduardo Marbán | {REDACTED} Heart Disease Regenerative Medicine Team Planning Award |
$38,980 |
| Basic Biology V | Paul W Noble | Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man |
$617,662 |
| Early Translational IV | Dr. Dan Gazit | Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing |
$5,121,514 |
| New Faculty Physician Scientist | Dr. Robert H Baloh | Human iPSC modeling and therapeutics for degenerative peripheral nerve disease |
$3,031,737 |
| Basic Biology IV | Eduardo Marbán | Mechanism of heart regeneration by cardiosphere-derived cells |
$1,367,604 |
| iPSC Consortia Award | Professor Clive Niels Svendsen | The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development |
$300,000 |
| Disease Team Therapy Development – Research | Professor Clive Niels Svendsen | Progenitor Cells Secreting GDNF for the Treatment of ALS |
$16,168,464 |
| Disease Team Therapy Planning I | Professor Clive Niels Svendsen | Stem Cells Secreting GDNF for the Treatment of ALS |
$63,487 |
| Disease Team Therapy Planning I | Dr. Dan Gazit | Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures. |
$107,622 |
| Tools and Technologies II | Professor Clive Niels Svendsen | Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. |
$1,933,022 |
| Early Translational II | Dr. Dan Gazit | Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures |
$1,927,698 |
| Research Leadership | Dr. Barry R Stripp | Epithelial progenitors and the stromal niche as therapeutic targets in lung disease |
$4,841,830 |
| Transplantation Immunology | Dr. Terrence Town | Role of HLA in neural stem cell rejection using humanized mice |
$1,119,385 |
| Disease Team Research I | Eduardo Marbán | Autologous cardiac-derived cells for advanced ischemic cardiomyopathy |
$5,560,232 |
